Hendi Pharmaceutical: The company plans to make a subscription capital contribution of 30 million yuan, accounting for 17.96% of the total subscription capital contribution of Zhigende Venture Capital in the first phase.

Hengdai Pharmaceuticals announced that the company, along with Shanghai Hongfu Private Equity Fund Management Co., Ltd. and Shengzhou Xinfag Equity Investment Partnership, jointly invested in the establishment of Shengzhou Zhide Entrepreneurial Investment Partnership, with an initial capital of 167 million yuan, solely for the purpose of investing in Shanghai Zhimeng Medical Technology Co., Ltd. The company, as a limited partner, has subscribed for a capital of 30 million yuan, accounting for 17.96% of the total initial capital of Zhidu Entrepreneurial Investment.